




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CPRIT Legislative Appropriations Request for the 2022-23 Biennium

Senate Finance Committee

February 9, 2021



2022-23 LAR: Requested Items

1. Exceptional Item: Adjustment for 552% Increase in CPRIT's Statewide Cost Allocation Plan (SWCAP) Share of Statewide Support Services
2. 10% Increase in Authority for the Chief Scientific Officer Exempt Salary

****All requested items require appropriations authority only, no additional funding.****



Exceptional Item Request

CPRIT requires a permanent adjustment of \$450,000 for CPRIT's Statewide Cost Allocation Plan (SWCAP) share of statewide support services based on a recently received notice of a 552% increase to \$448,525 (from \$68,844) that cannot be absorbed in CPRIT's annual budget



2022-23 LAR: CSO Exempt Salary Increase

Requires skill set of high-level health science center MD/PhD research administrator (medical school dean, comprehensive cancer center director, cancer research division head)

- Request 10% increase from \$553,500 to \$608,850
- Other than a 2.5% COLA, salary authorization not adjusted since 2013
- Comparable positions now average \$819,960



Questions?



2022-23 LAR: Appendix

- 1) CPRIT Background**
- 2) COVID-19 Impact on CPRIT**



In 2007,

Texans voted overwhelmingly in favor of a constitutional amendment creating the Cancer Prevention and Research Institute of Texas (CPRIT).

On November 5, 2019, Texas voters approved a constitutional amendment providing an additional \$3 billion to CPRIT, for a total \$6 billion investment in cancer research and prevention efforts across Texas, the second largest source of funding for cancer research in the world.



Invest in the research prowess of Texas institutions.



Create and expand the life science infrastructure in Texas and add high-quality jobs.



Expedite innovation in research and breakthroughs in prevention and cures.

Investing in Research Prowess in Texas Research Entities

- **218 stellar researchers and their labs** recruited to Texas institutions
- Texas achieved **3 NCI comprehensive cancer centers** – previously only MD Anderson
- **\$1.90 billion** in grants awarded to Texas research entities
- **\$1.569 billion** in direct follow-on funding raised by CPRIT academic research grantees
- **55 core facilities** at Texas institutions to provide access to cutting-edge shared technology

James Allison
2018 Nobel Prize in
Physiology or Medicine



▶ Accelerating **Innovation** in Research

165 CPRIT-funded Clinical Studies: 26,840 Patients

- **Interventional**
 - **108 studies**
 - **8,242 patients**

- **Observational**
 - **57 studies**
 - **18,598 patients**



▶ Creating and Expanding Life Science Infrastructure

Supported the Establishment, Expansion or Relocation of 42 Companies
with a CPRIT commitment of \$479.9 million




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

November 2020

► Create and Expand Life Science Infrastructure


Follow-on funds raised by academic research grantees and CPRIT-funded companies exceed contracted awards by \$2.60 Billion



▶ Enhancing **Innovation** in Prevention

- 6.8 million services provided
- 3.7 million education and training services for the public and professionals
- 3.1 million clinical services:
 - Breast, cervical, colorectal, lung screenings & diagnostics
 - Hepatitis B & C screenings
 - HPV & Hepatitis B vaccinations
 - Tobacco cessation counseling and treatment
 - Genetic testing and counseling
 - Survivor programs and services

COUNTIES OF RESIDENCE OF PEOPLE SERVED
BY CPRIT PREVENTION PROJECTS



**CPRIT has funded \$278 million for 244
prevention projects at 53 Texas organizations**



► CPRIT: Investing in a Cancer-Fighting Ecosystem

\$2.66 Billion Invested as of November 2020

Investment	Direct Return in FY 2020	Value
All Program Investments	<ul style="list-style-type: none">➤ 8,558 jobs in annual employment➤ \$442.1 million in personal income➤ \$1.2 billion in total expenditures➤ \$167.9 million in retail sales➤ \$50.9 million in state and local tax receipts➤ \$637.8 million in gross product	<ul style="list-style-type: none">• CPRIT is catalyzing the Texas life sciences ecosystem directly and thru the entire cancer healthcare continuum.• If Texas achieves a concentration in the biomedical industry by 2045 equivalent to that of the US, incremental gains will include \$17.8 billion in annual gross product and 151,270 jobs.



CPRIT Responds to COVID-19

Operationally:

- Remote Work Policy
- Cancelled all travel – onsite compliance visits now held virtually
- Cancelled biennial conference scheduled July 2020
- Oversight Committee quarterly meetings held virtually
- Despite pandemic, no impact to fulfilling CPRIT's core functions and statutory obligations

Grant Review and Administration:

- All peer review continues virtually
- Created COVID-19 workgroup to rapidly respond to grantee issues
- Working with the Office of the Governor, issued guidance permitting reimbursement of certain COVID-19 related grantee expenses
- Reimbursed \$3.3 million in COVID-19 related grantee expenses
- Awarded full slate of grants for FY 2020, expect to do so for FY 2021
- Grantees responded quickly to continue research, clinical trials, and prevention services.



COVID-19's Enduring Impact on Cancer

Decreased Cancer Services

- Pandemic shut down most preventive screenings and clinical trial enrollment
- CPRIT grantees provided 60% fewer screenings March 1-August 31 than previous six months due to COVID-19
- NCI modeling projects 10,000 more deaths from breast and colorectal cancer over next 10 years due to diagnoses delayed by COVID-19

CPRIT Research Helps COVID-19

- CPRIT-funded specialized microscope at UT Austin helped create 3D map of COVID-19 virus spike protein – used as blueprint for vaccines on the market now
- CPRIT drug developed for respiratory complications caused by cancer treatments now in clinical trials for COVID-19 respiratory problems
- Discovery research findings related to cancer at Texas A&M University, UTHealth and UTMB may lead to new insights for antibody treatments for coronaviruses
- CPRIT-funded facility contracted to manufacture vaccine

